Melanoma is an extremely difficult disease to treat. Chemotherapy is notoriously ineffective with a negligible long-term remission rate. Recent studies have established that inhibition of BRAF signaling induces massive melanoma cell death leading to response rates exceeding 50% in patients who test positive for the BRAFV600E mutation. Responses unfortunately are transient, lasting on average 6.8 months and eventually all patients'progress or relapse. In contrast, immunotherapy can produce long-lasting cures in a small minority of patients. Combination of these approaches is therefore extremely attractive. BRAF inhibition induces cell death and the release of melanoma antigens in patients. This is exciting for the melanoma field because chemotherapy does not reliably kill melanoma tumors in patients. Recent studies suggest that dying tumor cells can be excellent sources of antigen for immunotherapy. BRAF inhibition therefore, because it causes massive tumor cell death, represents a unique opportunity to develop novel effective immunotherapies. This proposal aims to identify immune mediated strategies able to potentiate clinical remissions induced by BRAF inhibition. The study proposed herein provides the first comprehensive assessment of the contribution of cutaneous DC and macrophages to the development, or the lack thereof, of therapeutic immunity to BRAF inhibitors using an inducible model of BRAF-driven tumors. We find this to be of great importance as endogenous vaccination due to BRAF-inhibition-induced melanoma cell death could offer a novel approach to melanoma immunotherapy. Such an approach could overcome numerous drawbacks in the vaccination strategies currently in use. In the last ten years, our group of investigators has provided evidence that the expansion of endogenous DCs followed by their activation might be a valid strategy to promote antitumor immunity in several mouse tumor models. Here, we propose advancing a step further and testing whether combining BRAF inhibitors to increase tumor antigen availability, together with vaccination strategies aimed at expanding and activating tumor-associated CD103+ DC in situ while eliminating tumor-associated immunosuppressive APC via CSF-1R Ab (already in cancer Phase I trial), could prolong response to BRAF therapy. Combination therapy with BRAF inhibitors and immunotherapy is urgently needed by melanoma patients. Results of this study are expected to provide a rationale for the design of key clinical trials to treat this devastating disease.

Public Health Relevance

Effective therapies for melanoma are a critical need as cure rates for advanced disease are less than 5%. Recent studies established that 50% melanoma lesions express Braf mutations and that BRAF inhibition induces impressive, yet brief responses whereas immunotherapy can produce long-lasting cures in a small minority of patients. The overall goal of this project is to identify immune mediated strategy that could potentiate BRAF response using a BRAF V600E inducible spontaneous tumor mouse melanoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
9R01CA173861-03A1
Application #
8439839
Study Section
Special Emphasis Panel (ZRG1-OTC-C (03))
Program Officer
Yovandich, Jason L
Project Start
2008-12-01
Project End
2018-01-31
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
3
Fiscal Year
2013
Total Cost
$423,750
Indirect Cost
$173,750
Name
Icahn School of Medicine at Mount Sinai
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Qing, Xiaoping; D Rogers, Lindsay; Mortha, Arthur et al. (2016) iRhom2 regulates CSF1R cell surface expression and non-steady state myelopoiesis in mice. Eur J Immunol 46:2737-2748
Kidd, Brian A; Wroblewska, Aleksandra; Boland, Mary R et al. (2016) Mapping the effects of drugs on the immune system. Nat Biotechnol 34:47-54
Sawai, Catherine M; Babovic, Sonja; Upadhaya, Samik et al. (2016) Hematopoietic Stem Cells Are the Major Source of Multilineage Hematopoiesis in Adult Animals. Immunity 45:597-609
Jiao, Jingjing; Ooka, Kohtaro; Fey, Holger et al. (2016) Interleukin-15 receptor α on hepatic stellate cells regulates hepatic fibrogenesis in mice. J Hepatol 65:344-53
Chudnovskiy, Aleksey; Mortha, Arthur; Kana, Veronika et al. (2016) Host-Protozoan Interactions Protect from Mucosal Infections through Activation of the Inflammasome. Cell 167:444-456.e14
Maier, Barbara B; Hladik, Anastasiya; Lakovits, Karin et al. (2016) Type I interferon promotes alveolar epithelial type II cell survival during pulmonary Streptococcus pneumoniae infection and sterile lung injury in mice. Eur J Immunol 46:2175-86
Khan, Jalal A; Mendelson, Avital; Kunisaki, Yuya et al. (2016) Fetal liver hematopoietic stem cell niches associate with portal vessels. Science 351:176-80
Salmon, Hélène; Idoyaga, Juliana; Rahman, Adeeb et al. (2016) Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. Immunity 44:924-38
Chakraborty, Rikhia; Burke, Thomas M; Hampton, Oliver A et al. (2016) Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood 128:2533-2537
Herbin, Olivier; Bonito, Anthony J; Jeong, Seihwan et al. (2016) Medullary thymic epithelial cells and CD8α(+) dendritic cells coordinately regulate central tolerance but CD8α(+) cells are dispensable for thymic regulatory T cell production. J Autoimmun 75:141-149

Showing the most recent 10 out of 35 publications